Chimeric antigen receptor-T (CAR-T) cell therapy has been shown to be superior to
conventional therapy in patients with refractory and relapsed B-cell non-Hodgkin's lymphoma.
However, prior clinical studies and real-world data suggest that approximately 30-40% of
cases of drug resistance still occur after CAR-T cell therapy, and approximately 50-60% of
cases have recurrent disease progression over time of infusion. Our previous research
suggests that the low expression of NOXA protein may be an important biomarker for the
treatment of drug resistance of CAR-T cells. Up regulating the expression of NOXA through
histone deacetylase (HDAC) inhibitors can improve drug resistance and significantly improve
the therapeutic effect of CAR-T cells. The purpose of this study was to screen the population
with low NOXA expression and proposed to receive CAR-T treatment, and to evaluate the safety
and effect of intervention containing HDAC inhibitor (chidamide) bridging therapy on CAR-T
efficacy.